Flow cytometric assay for genotyping cytochrome P450 2C9 and 2C19: Comparison with a microelectronic DNA array

American Journal of PharmacoGenomics

Volumn 4, Issue 3, 2004, Pages 199-207

  Pickering, Jerry W ^a   McMillin, Gwendolyn A ^a,b   Gedge, Friederike ^a   Hill, Harry R ^a,b   Lyon, Elaine ^a,b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; DRUG EFFICACY; DRUG METABOLISM; FLOW CYTOMETRY; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; DNA PRIMERS; ELECTROCHEMISTRY; FLOW CYTOMETRY; GENOTYPE; HUMANS; MICROSPHERES; MIXED FUNCTION OXYGENASES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3042758660     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404030-00007     Document Type: Article

References (27)

1. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34: 83-448
2. Oscarson M, Ingelman-Sundberg M, Daly AK, et al. Human cytochrome P450 (CYP) alleles [online]. Available from URL: http://www.imm.ki.se/CYPalleles [Accessed 2003 Aug 31]
3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37
4. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55
5. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-5
6. Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology 2000; 61: 174-83
7. Desta Z, Zhao X, Shin J-G, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
8. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269: 15419-22
9. Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286: 1490-5
10. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70
11. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63
12. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9
13. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9
14. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8
15. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92
16. Dean FB, Hosono S, Fang L, et al. Comprehensive human genome amplification using multiple displacement amplification. Proc Natl Acad Sci U S A 2002; 99: 5261-6
17. Radi D, Esmaili L, Lally B, et al. Electrochemical detection of CYP2D6, CYP2C9 and CYP2C19 polymorphisms using eSensor™ DNA microarrays [abstract]. J Mol Diagn 2002; 4: 236
18. Romkes M, Faletto MB, Blaisdell JA, et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30: 3247-55
19. Xie H-G, Kim RB, Wood AJJ, et al. Molecular basis for ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001; 41: 815-50
20. Shi MM. Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes. Am J Pharmacogenomics 2002; 2: 197-205
21. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003; 49: 542-51
22. Borlak J, Thum T. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clin Chem 2002; 48: 1592-4
23. Lyon E. Mutation detection using fluorescent hybridization probes and melting curve analysis. Expert Rev Mol Diagn 2001; 1: 92-101
24. Umek RM, Lin SW, Vielmetter J, et al. Electronic detection of nucleic acids: a versatile platform for molecular diagnostics. J Mol Diagn 2001; 3: 74-84
25. Taylor JD, Briley D, Nguyen Q, et al. Flow cytometric platform for high-throughput single nucleotide polymorphism analysis. Biotechniques 2001; 30: 661-6
26. Iannone MA, Li MS, Taylor JD, et al. A microsphere-based assay for multiplexed single nucleotide polymorphism analysis using single base chain extension. Genome Res 2000; 10: 549-57
27. Ye F, Li MS, Taylor JD, et al. Fluorescent microsphere-based readout technology for multiplexed human single nucleotide polymorphism analysis and bacterial identification. Hum Mutat 2001; 17: 305-16